First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. | Publicación